# US 2010/0166793 A1 · Protease-resistant modified seb and vaccine containing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166793 A1
- Document ID: US20100166793A1
- Status: Published application
- Kind: A1
- Application number: 12/644,952
- Filed: 2009-12-22
- Published: 2010-07-01
- Earliest claimed: 2003-09-05
- Assignees: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute; Kowa Company, Ltd.
- Inventors: Toshihiro NAKASHIMA; Takumi Sasaki; Tsukasa Nishihara; Sumiyo Takemoto; Atsuko Sakata; Masao Ohkuchi; Tomoyuki Koshi; Toshiyuki Edano
- Web page: https://patentgrep.com/patent/US20100166793A1

## CPC

- C07K 14/31: from Staphylococcus (G)
- A61P 31/04: Antibacterial agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A modified Staphylococcal enterotoxin B (SEB) having resistance to a protease and a reduced toxicity and a vaccine comprising said modified SEB are provided. A modified SEB which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with any other amino acid, or a derivative thereof and a vaccine comprising said modified SEB or a derivative thereof.

## Claims

### Claim 1

A modified Staphylococcal enterotoxin B (SEB) having an amino acid substitution to allow for resistance to a protease, or a derivative thereof.

### Claim 2 (depends on 1)

The modified SEB or a derivative thereof of claim 1 which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with any other amino acid.

### Claim 3 (depends on 2)

The modified SEB or a derivative thereof of claim 2 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with serine.

### Claim 4 (depends on 1)

The modified SEB or a derivative thereof of claim 1 which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein the asparagine at 23-position is substituted with tyrosine.

### Claim 5 (depends on 1)

The modified SEB or a derivative thereof of claim 1 wherein said protease is selected from trypsin and cathepsin B.

### Claim 6 (depends on 1)

A vaccine comprising as an active ingredient the modified SEB or a derivative thereof of claim 1.

### Claim 7 (depends on 6)

The vaccine of claim 6 in an amount sufficient for treatment of opportunistic infections and severe diseases caused by a toxin produced by bacteria resistant to antibiotics.

### Claim 8 (depends on 6)

The vaccine of claim 6 in an amount sufficient for treatment of type I allergic disease.

### Claim 9 (depends on 6)

The vaccine of claim 6 in a form for oral administration.
